Mortality risk of opioid substitution therapy with methadone versus buprenorphine: A retrospective cohort study

The Lancet Psychiatry

Volumn 2, Issue 10, 2015, Pages 901-908

  Kimber, Jo ^a,c   Larney, Sarah ^a,d   Hickman, Matthew ^e   Randall, Deborah ^b   Degenhardt, Louisa ^a,f  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d BROWN UNIVERSITY   (United States)

^e UNIVERSITY OF BRISTOL   (United Kingdom)

^f UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE; METHADONE;

ADULT; AGE; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG OVERDOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OPIATE ADDICTION; OPIATE SUBSTITUTION TREATMENT; RETROSPECTIVE STUDY; SEX; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; ADVERSE EFFECTS; CAUSE OF DEATH; KAPLAN MEIER METHOD; MIDDLE AGED; OPIOID-RELATED DISORDERS; YOUNG ADULT;

ADULT; BUPRENORPHINE; CAUSE OF DEATH; COHORT STUDIES; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; METHADONE; MIDDLE AGED; MORTALITY; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84942982381     PISSN: 22150366     EISSN: 22150374     Source Type: Journal    
DOI: 10.1016/S2215-0366(15)00366-1     Document Type: Article

References (37)

1. Degenhardt L, Bucello C, Mathers B, et al. Mortality among regular or dependent users of heroin and other opioids: a systematic review and meta-analysis of cohort studies. Addiction 2011, 106:32-51.
2. Clausen T, Waal H, Thoresen M, Gossop M Mortality among opiate users: opioid maintenance therapy, age and causes of death. Addiction 2009, 104:1356-1362.
3. Degenhardt L, Randall D, Hall W, Law M, Butler T, Burns L Mortality among clients of a state-wide opioid pharmacotherapy program over 20 years: risk factors and lives saved. Drug Alcohol Depend 2009, 105:9-15.
4. Risser D, Hönigschnabl S, Stichenwirth M, Pfudl S, Sebald D, Kaff A Mortality of opiate users in Vienna, Austria. Drug Alcohol Depend 2001, 64:251-256.
5. Soyka M, Apelt SM, Lieb M, Wittchen HU One-year mortality rates of patients receiving methadone and buprenorphine maintenance therapy: a nationally representative cohort study in 2694 patients. J Clin Psychopharmacol 2006, 26:657-660.
6. Cornish R, Macleod J, Strang J, Vickerman P, Hickman M Risk of death during and after opiate substitution treatment in primary care: prospective observational study in UK General Practice Research Database. BMJ 2010, 341:928.
7. WHO model list of essential medicines 2011, WHO, World Health Organization, Geneva. 17th edition.
8. Lewis JW Buprenorphine. Drug Alcohol Depend 1985, 14:363-372.
9. Kress HG Clinical update on the pharmacology, efficacy and safety of transdermal buprenorphine. Eur J Pain 2009, 13:219-230.
10. Cremeans C, Gruley E, Kyle DJ, Ko MC Roles of μ-opioid receptors and nociceptin/orphanin FQ peptide receptors in buprenorphine-induced physiological responses in primates. J Pharmacol Exp Ther 2012, 343:72-81.
11. Auriacombe M, Franques P, Tignol J Deaths attributable to methadone vs buprenorphine in France. JAMA 2001, 285:3.
12. Hser YI, Saxon AJ, Huang D, et al. Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial. Addiction 2014, 109:79-87.
13. Mattick RP, Breen C, Kimber J, Davoli M Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev 2014, 2. CD002207.
14. Burns L, Randall D, Hall WD, et al. Opioid agonist pharmacotherapy in New South Wales from 1985 to 2006: patient characteristics and patterns and predictors of treatment retention. Addiction 2009, 104:1363-1372.
15. Burns L, Gisev N, Larney S, et al. A longitudinal comparison of retention in buprenorphine and methadone treatment for opioid dependence in New South Wales, Australia. Addiction 2015, 110:646-655.
16. Lingford-Hughes AR, Welch S, Peters L, Nutt DJ BAP updated guidelines: evidence-based guidelines for the pharmacological management of substance abuse, harmful use, addiction and comorbidity: recomendations from BAP. J Psychopharmacol 2012, 26:899-952.
17. Methadone and buprenorphine for the management of opioid dependence: NICE technology appraisal guidance 114 2007, NICE, National Institute for Health and Clinical Excellence, London.
18. Clark HW Office-based practice and opioid-use disorders. N Engl J Med 2003, 349:928-930.
19. Schackman BR, Merrill JO, McCarty D, Levi J, Lubinski C Overcoming policy and financing barriers to integrated buprenorphine and HIV primary care. Clin Infect Dis 2006, 43(suppl 4):S247-S253.
20. Jones ES, Moore BA, Sindelar JL, O'Connor PG, Schottenfeld RS, Fiellin DA Cost analysis of clinic and office-based treatment of opioid dependence: results with methadone and buprenorphine in clinically stable patients. Drug Alcohol Depend 2009, 99:132-140.
21. Caplehorn JR Deaths in the first two weeks of maintenance treatment in NSW in 1994: identifying cases of iatrogenic methadone toxicity. Drug Alcohol Rev 1998, 17:9-17.
22. Buster MC, van Brussel GH, van den Brink W An increase in overdose mortality during the first 2 weeks after entering or re-entering methadone treatment in Amsterdam. Addiction 2002, 97:993-1001.
23. Caplehorn JR, Drummer O Mortality associated with New South Wales methadone programs in 1994: lives lost and saved. Med J Aust 1999, 170:104-109.
24. International statistical classification of diseases and related health problems 1993, WHO, World Health Organization, Geneva. 10th edn.
25. Randall D, Roxburgh AD, Gibson A, Degenhardt L Mortality among people who use illicit drugs: A toolkit for classifying major causes of death (NDARC Technical Report no. 301) 2009, National Drug and Alcohol Research Centre, Sydney.
26. Davoli M, Bargagli AM, Perucci CA, et al. Risk of fatal overdose during and after specialist drug treatment: the VEdeTTE study, a national multi-site prospective cohort study. Addiction 2007, 102:1954-1959.
27. Schneeweiss S Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics. Pharmacoepidemiol Drug Saf 2006, 15:291-303.
28. Cousins G, Teljeur C, Motterlini N, McCowan C, Dimitrov BD, Fahey T Risk of drug-related mortality during periods of transition in methadone maintenance treatment: a cohort study. J Subst Abuse Treat 2011, 41:252-260.
29. McCowan C, Kidd B, Fahey T Factors associated with mortality in Scottish patients receiving methadone in primary care: retrospective cohort study. BMJ 2009, 338:b2225.
30. Kimber J, Copeland L, Hickman M, et al. Survival and cessation in injecting drug users: prospective observational study of outcomes and effect of opiate substitution treatment. BMJ 2010, 341:c3172.
31. Darke S, Mills K, Ross J, Teeson M Rates and correlates of mortality amongst heroin users: findings from the Australian Treatment Outcome Study (ATOS), 2001-2009. Drug Alcohol Depend 2011, 115:190-195.
32. Roxburgh AD, Burns L Accidental drug-induced deaths due to opioids in Australia 2014, National Drug and Alcohol Research Centre, Sydney.
33. Degenhardt L, Conroy E, Gilmour S, Hall W The effect of a reduction in heroin supply on fatal and non-fatal drug overdoses in New South Wales, Australia. Med J Aust 2005, 182:20-23.
34. Peles E, Schreiber S, Adelson M 15-year survival and retention of patients in a general hospital-affiliated methadone maintenance treatment (MMT) center in Israel. Drug Alcohol Depend 2010, 107:141-148.
35. Bauer SM, Loipl R, Jagsch R, et al. Mortality in opioid-maintained patients after release from an addiction clinic. Eur Addict Res 2008, 14:82-91.
36. Hickman M, Vickerman P, Robertson R, Macleod J, Strang J Promoting recovery and preventing drug-related mortality: competing risks?. J Public Health (Oxf) 2011, 33:332-334.
37. Kakko J, Gronbladh L, Svanborg KD, et al. A stepped care strategy using buprenorphine and methadone versus conventional methadone maintenance in heroin dependence: a randomized controlled trial. Am J Psychiatry 2007, 164:797-803.